BeOne Medicines Ltd. (ONC) Q3 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Beone Medicines Ltd. Class A.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.599 Good day, everyone. Welcome to B1 Medicine's Q3 2025 earnings call webcast. 00:00:05.599 -- 00:00:08.964 All lines have been placed on mute to prevent any background noise. 00:00:08.964 -- 00:00:12.209 After the speaker's remarks, there will be a question and answer session. 00:00:12.209 -- 00:00:16.072 At this time, I would like to turn the call over to the company. 00:00:17.517 -- 00:00:19.700 Hello and welcome. Thanks for joining us today. 00:00:19.700 -- 00:00:23.265 I'm Dan Maller, head of investor relations at B1 Medicines. 00:00:23.265 -- 00:00:27.371 Before we begin, please note that you can find additional materials, including a replay 00:00:27.371 -- 00:00:32.254 of today's webcast and presentations, on the investor relations section of our website, 00:00:32.254 -- 00:00:34.254 ir.b1medicines.com. 00:00:35.098 -- 00:00:38.522 I would like to remind all participants that during this call, we may make forward-looking 00:00:38.522 -- 00:00:42.308 statements regarding, among other things, the company's future prospects and business 00:00:42.308 -- 00:00:47.014 strategy. Actual results may differ materially from those indicated in the forward-looking 00:00:47.014 -- 00:00:52.182 statements as a result of various factors, including those risks discussed in our most 00:00:52.182 -- 00:00:55.668 recent periodic report filed with the SEC. 00:00:55.668 -- 00:00:59.392 Please also carefully review the forward-looking statements disclaimer in the slide deck 00:00:59.392 -- 00:01:01.894 that accompanies this presentation. 00:01:01.894 -- 00:01:06.459 Reconciliations between GAAP and non-GAAP financial measures discussed on this call are 00:01:06.459 -- 00:01:10.603 provided in the appendix to our presentation, which is posted to our i...